Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | CTSS | P25774 | 9/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ECE1 | P42892 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6447475 | 1.00 | PKM (0.50) | PKMSMN1; SMN2CTSSHTTCAPN1 | |
| SCHEMBL9852719 | 0.87 | SMN1; SMN2 (0.53) | PKMSMN1; SMN2CTSSHTTCAPN1 | |
| SCHEMBL1038171 | 0.84 | ECE1 (0.42) | HTTPOLBGAAECE1 | |
| SCHEMBL5781357 | 0.81 | SMN1; SMN2 (0.53) | PKMSMN1; SMN2CTSSHTTCAPN1 | |
| SCHEMBL5516579 | 0.78 | PKM (0.58) | PKMSMN1; SMN2CTSSHTTCAPN1 | |
| SCHEMBL6801263 | 0.78 | CTSS (0.69) | PKMSMN1; SMN2CTSSHTTCAPN1 | |
| SCHEMBL6802863 | 0.78 | CTSS (0.69) | PKMSMN1; SMN2CTSSHTTCAPN1 | |
| SCHEMBL5516574 | 0.78 | PKM (0.58) | PKMSMN1; SMN2CTSSHTTCAPN1 | |
| SCHEMBL7027854 | 0.78 | CTSS (0.69) | PKMSMN1; SMN2CTSSHTTCAPN1 | |
| SCHEMBL6801412 | 0.78 | HTT (0.56) | PKMSMN1; SMN2CTSSHTTCAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | PHARMACIA & UPJOHN COMPANY LLC | 2005-06-16 | — | — | US | disclosed |
| EP-1392315-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002100410-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| US-5753652-A | Antiretroviral hydrazine derivatives | NOVARTIS CORPORATION (US) | 1998-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, BACE2 | PKM 2587/4885SMN1; SMN2 1200/4885CTSS 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.